Real-world data of subcutaneous trastuzumab and intravenous pertuzumab as neoadjuvant therapy for localized HER2+ breast cancer in Panama

Simple item page
dc.contributor.authorCastillero, Franklin
dc.contributor.authorCastillo, Omar
dc.contributor.authorLim-Law, María
dc.contributor.authorMartin, Cristiane
dc.contributor.authorMontano, Lilian
dc.contributor.authorBenitez, Stephanie
dc.contributor.authorSamudio, Jaime
dc.date.accessioned2026-06-18T14:19:48Z
dc.date.issued2021-04-15
dc.description.abstractThe aim of this study is to determine the effectiveness of subcutaneous trastuzumab in combination with intravenous pertuzumab and chemotherapy for patients with HER2-overexpressing localized breast cancer treated in our center. Methods: This was a descriptive, retrospective, real-world study. Results: Of 156 patients, pathological complete response (pCR) was achieved in 64.1%. A multivariate analysis showed a relationship with a negative hormone receptor (HR) expression and a HER2 score of 3+ by immunohistochemistry. Relapse-free survival (RFS) was higher in patients with pCR. Conclusion: Neoadjuvant therapy with dual blockade using intravenous pertuzumab and subcutaneous trastuzumab for HER2+ localized breast cancer in routine clinical practice resulted in a 64.1% pCR rate. Additionally, this outcome was related to a negative HR expression and HER2 overexpression, and correlated with higher relapse-free survival.
dc.identifier.citationRodriguez, F. C., Castillo-Fernandez, O., Lim-Law, M., Palacios, C. M., Montano, L., Benitez, S., & Samudio, J. (2021). Real-world data of subcutaneous trastuzumab and intravenous pertuzumab as neoadjuvant therapy for localized HER2+ breast cancer in Panama. Breast Cancer Management, 10(1). https://doi.org/10.2217/bmt-2021-0003
dc.identifier.doi10.2217/bmt-2021-0003
dc.identifier.urihttps://cancer.senacyt.gob.pa/handle/123456789/140
dc.language.isoen
dc.publisherBreast Cancer Management
dc.relation.ispartofseries10; 1
dc.subjectanthracyclines
dc.subjectbreast cancer
dc.subjectdisease-free survival
dc.subjecteffectiveness
dc.subjectneoadjuvant therapy
dc.subjectpathological complete response
dc.subjectpertuzumab
dc.subjectreal-world data
dc.subjecttoxicity
dc.subjecttrastuzumab
dc.titleReal-world data of subcutaneous trastuzumab and intravenous pertuzumab as neoadjuvant therapy for localized HER2+ breast cancer in Panama
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Real-world data of subcutaneous trastuzumab and intravenous pertuzumab as neoadjuvant therapy for localized HER2 breast cancer in Panama.cleaned.pdf
Size:
1.2 MB
Format:
Adobe Portable Document Format
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download

Collections

Medicina personalizada y terapias dirigidas